An observational study in Post-Menopausal Osteoporosis, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Canada. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2016-03-04.
Sponsored by Novartis Pharmaceuticals · Observational
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 1,551 is above the median of 174 across 446 observational studies indexed under Osteoporosis.
Browse Osteoporosis studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Ambulatory Female patients, at least 45 years of age, diagnosed with osteoporosis and taking either Zelodronic acid or any other oral bisphosphonates (OBP) as per the current Canadian monograph
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Drug: zoledronic acid
Drug: Any oral bisphosphonates marketed in Canada
Percent change in lumbar spine BMD as measured by dual energy x-ray absorptiometry (DXA)
Time frame: 4 years
change in femoral neck BMD as measured by dual energy x-ray absorptiometry (DXA)
Time frame: 4 years
change in hip BMD as measured by dual energy x-ray absorptiometry (DXA)
Time frame: 4 years
Percent change in hip BMD as measured by dual energy x-ray absorptiometry (DXA)
Time frame: 4 years
Risk for fractures
Time frame: 4 years
Burden of illness, health care resource utilization, and loss of productivity
Time frame: 4 years
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals